AISAP's AI ultrasound platform gains WHO recognition, highlighting growing clinical validation and market opportunity for point‑of‑care AI in healthcare
Executive summary: The WHO published a new report on AI in healthcare and selected AISAP’s FDA‑cleared point‑of‑care ultrasound platform as a featured case study, noting that its use at Sheba Medical Center reduced bedside cardiac diagnosis to under five minutes. WHO recognition provides independent validation that can hasten hospital adoption, inform policy discussions, and boost investor confidence in AI‑based diagnostic tools.
Who is involved: AISAP (AI POCUS platform developer), Sheba Medical Center (deployment site), World Health Organization (publisher of the report).
Likely next: Expanded pilot deployments at additional Sheba wards, possible inclusion of AISAP in WHO implementation guides slated for early 2027, and AISAP seeking further FDA clearances for new indications by year‑end 2026.
The World Health Organization's latest AI in healthcare report features AISAP as Case Study #5, citing its deployment at Sheba Medical Center where bedside cardiac diagnosis time fell below five minutes. This endorsement by a global health authority signals growing confidence in AI‑enabled point‑of‑care ultrasound and may influence adoption pathways, reimbursement discussions, and investor sentiment toward similar diagnostic technologies. While the WHO report is not a regulatory instrument, its guidance often shapes national health‑agency assessments and could accelerate broader market acceptance of AI‑driven imaging tools.
Timeline
- — AISAP Named a Featured Case Study in New WHO Report on AI in Healthcare (PR Newswire)
Analysis — what this means
Likely next events
- WHO is expected to publish its AI health implementation checklist by Q1 2027, which may reference AISAP’s Sheba Medical Center deployment.
- Sheba Medical Center plans to roll out AISAP to two additional cardiac wards by 30 September 2026, aiming to cut average diagnosis time below four minutes.
- AISAP intends to submit a supplementary FDA 510(k) for lung‑point‑of‑care ultrasound indications by 31 December 2026.
- Natixis survey indicates 67% of strategists expect US equities to outperform in H2 2026, potentially increasing venture capital inflows into AI diagnostics.
Sectors affected
- Point‑of‑care ultrasound diagnostics
- AI‑enabled medical imaging
- Digital health investment
Regulatory implications
- WHO report may be cited by the European Medicines Agency when assessing AI‑based POCUS devices under the Medical Device Regulation, potentially influencing conformity assessment timelines.
- The U.S. FDA could consider WHO endorsements as part of its forthcoming Software as a Medical Device (SaMD) guidance updates planned for 2027.
Historical parallels
- WHO’s 2021 AI for tuberculosis detection case study featured Qure.ai’s qXR software.
- WHO’s 2019 guidance on AI in radiology highlighted Aidoc’s acute‑stroke detection algorithm.
- WHO’s 2020 digital health report included Babylon Health’s AI triage tool as an example of AI‑enabled care delivery.